Medical XpressDetecting Multiple Cancers and Other Diseases From a Single Blood Sample

UCLA’s MethylScan blood test detected 63% of cancers across all stages and nearly 80% of liver cancers in high-risk patients at 98% and 90% specificity respectively, using a single cfDNA methylation assay estimated at under $20 per run. The test simultaneously identifies tissue of origin and distinguishes between liver disease subtypes, potentially reducing the need for invasive biopsies.

Clinical Considerations

• Multi-cancer detection from one blood draw includes liver, lung, ovarian, and stomach cancers, with tissue-of-origin mapping to direct follow-up imaging.
• Early-stage sensitivity of 55% remains a limitation, but liver cancer surveillance in cirrhosis and HBV patients reached nearly 80% detection at under 10% false positive rate.
• Disease classification beyond cancer correctly identified liver disease subtype in 85% of patients, challenging the need for routine diagnostic biopsies in high-risk populations.
• Cost efficiency through background DNA removal reduces sequencing depth required, a meaningful barrier in broad population screening programs.

Practice Applications

• Monitor MethylScan trial data as prospective studies launch; early enrollment opportunities may exist for high-risk oncology patients.
• Identify your cirrhosis and HBV patient panels now as the population most likely to benefit from early adoption.
• Counsel patients asking about multi-cancer screening tests that MethylScan is promising but not yet validated for clinical use.
• Engage multidisciplinary teams on tissue-of-origin mapping protocols to streamline follow-up imaging workflows when liquid biopsy signals emerge.

More in Early Detection